Evotec's Revised Blueprint Faces Its First Reality Check
Published on 08/13/2026 at 17:53 | Redaktion boerse-global.de
The gap between Evotec's 52-week high and its current share price now tells a story of its own. At 3.58 euros, the stock sits roughly 54 percent below the 7.75-euro peak reached in early November — a chasm that widened further on Thursday as the Bremen-based drug developer published its full first-half results.
The numbers confirmed what the market had already priced in since the July profit warning. Group revenue fell to 300.1 million euros for the first six months, down 19 percent from 371.2 million euros a year earlier. Adjusted EBITDA swung to a loss of 42.7 million euros from a modest minus 1.9 million euros in the prior-year period. The second quarter alone saw revenue drop 16.2 percent to 143.5 million euros.
Thursday's 6.2 percent decline to 3.58 euros brings the equity closer to its 52-week low of 3.19 euros than to its November peak. Long-term holders have absorbed a 46 percent loss over twelve months, while the year-to-date decline stands at 30 percent.
A Guidance Cut With a Silver Lining
Management reaffirmed the reduced full-year outlook first unveiled in July. Evotec now expects revenue between 570 and 610 million euros, down from the original 700 to 780 million euro range. The adjusted EBITDA forecast has been slashed from a break-even-to-plus-40-million band to a loss of 70 to 105 million euros.
What's notable is the company's explanation for the shortfall. Roughly 40 percent of the decline stems from delayed projects and milestone payments now expected to be recognized as revenue only in 2027. Another 45 percent traces to reduced contributions from new partnerships. That breakdown suggests a timing problem rather than a structural collapse — at least according to management's framing.
Should investors sell immediately? Or is it worth buying Evotec?
Supporting that interpretation, the Discovery & Preclinical Development segment outside strategic partnerships grew net sales by 28 percent in the first half, with revenue recognition anticipated from the fourth quarter onward.
Biologics Drag and a Stabilizing Balance Sheet
Just-Evotec Biologics saw revenue fall 29.3 percent to 72.3 million euros, though the comparison is flattered by a one-off license sale to Sandoz in the prior year that inflated the base figure. The company points to high capacity utilization and a broadening customer base as mitigating factors.
Liquidity stood at 465.6 million euros as of June 30, suggesting no immediate financial distress. The "Horizon" restructuring program — launched in March with plans to cut up to 800 positions and consolidate the global footprint from 14 to 10 sites by the end of 2027 — is expected to deliver 75 million euros in annual savings. For 2026, Evotec targets capturing 20 to 30 percent of that benefit.
The strategic review announced in May continues, and its outcome remains the key swing factor for the company's direction.
New Alliances Offer a Counterpoint
Despite the gloomy headline numbers, business development activity has continued. In early August, Evotec launched an AI-powered research collaboration with Odyssey Therapeutics focused on autoimmune and inflammatory diseases, followed by a partnership with Niagen Bioscience for preclinical development of candidate NB4168.
These deals demonstrate that operations remain active, even if they're unlikely to close the current revenue gap in the near term.
Evotec at a turning point? This analysis reveals what investors need to know now.
Analyst sentiment had already turned cautious before Thursday's release. Berenberg downgraded the stock from Buy to Hold in July, cutting its price target from 9.40 to 3.60 euros, while TD Cowen also moved to a Hold rating. Both assessments predate the full report, reflecting expectations rather than confirmation of the cut.
The stock had recovered roughly 10 percent over the seven trading sessions before Thursday, leaving it about 20 percent above its July low. An automated performance screen recently assigned a "D-rating," citing a negative average annual return over a decade — a historical observation rather than a predictive tool.
The next inflection point arrives in November with the third-quarter report. Until then, the strategic review remains the primary narrative driving this stock.
Ad
Evotec Stock: New Analysis - 13 August
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
